Keros Therapeutics (KROS) Asset Utilization Ratio (2020 - 2026)
Keros Therapeutics' (KROS) quarterly Asset Utilization Ratio came in at 0.45 in Q4 2025, up 7571.88% YoY from 0.01 in Q4 2024, and up 37.17% on a QoQ basis from 0.33 in Q3 2025.
Keros Therapeutics (KROS) Asset Utilization Ratio (2020 - 2026) Analysis & Trends
Keros Therapeutics (KROS) has 6 years of Asset Utilization Ratio data on file, last reported at 0.45 in Q4 2025.
- Quarterly Asset Utilization Ratio rose 7571.88% year-over-year to 0.45 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.45 (up 7571.88% YoY) and the FY2025 annual result came in at 0.51, up 6999.88% from the prior year.
- Asset Utilization Ratio climbed to 0.45 in Q4 2025, from 0.33 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.45 in Q4 2025 to a low of 0.0 in Q3 2023.
- A 5-year average of 0.12 and a median of 0.06 in 2022 frame the typical range for Asset Utilization Ratio.
- Annual changes were most pronounced in 2023 — Asset Utilization Ratio tumbled 99.98% — and 2025, when it jumped 60623.7%.
- Tracing KROS's Asset Utilization Ratio over 5 years: stood at 0.07 in 2021, then decreased by 13.25% to 0.06 in 2022, then slumped by 99.33% to 0.0 in 2023, then soared by 1255.36% to 0.01 in 2024, then jumped by 7571.88% to 0.45 in 2025.
- The last three Asset Utilization Ratio figures came in at 0.45 (Q4 2025), 0.33 (Q3 2025), and 0.3 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 0.20 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 0.69 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 0.90 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 0.13 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 0.54 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 0.13 |
| 10 | Keros Therapeutics | 217.61 Mn | -40.00 Mn | - | -0.55 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.55 |
| Dec 31, 2025 | 0.45 |
| Sep 30, 2025 | 0.33 |
| Jun 30, 2025 | 0.30 |
| Mar 31, 2025 | 0.31 |
| Dec 31, 2024 | 0.01 |
| Sep 30, 2024 | 0.00 |
| Jun 30, 2024 | 0.00 |
| Mar 31, 2024 | 0.00 |
| Dec 31, 2023 | 0.00 |
| Sep 30, 2023 | 0.00 |
| Dec 31, 2022 | 0.06 |
| Sep 30, 2022 | 0.15 |
| Jun 30, 2022 | 0.16 |
| Mar 31, 2022 | 0.15 |
| Dec 31, 2021 | 0.07 |
| Sep 30, 2021 | 0.00 |
| Jun 30, 2021 | 0.00 |
| Sep 30, 2020 | 0.02 |
| Jun 30, 2020 | 0.05 |